AT

Atrys Health SAMAD Atrys Stock Report

Last reporting period 30 Jun, 2023

Updated 18 Oct, 2024

Last price

Market cap $B

0.262

Micro

Exchange

XMAD - Bolsa de Madrid

ATRY.MC Stock Analysis

AT

Uncovered

Atrys Health SA is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-32/100

Low score

Market cap $B

0.262

Dividend yield

Shares outstanding

76.009 B

Atrys Health SA is a biomedical company, which engages in the research and development of diagnostic services. The company is headquartered in Madrid, Madrid and currently employs 2,397 full-time employees. The company went IPO on 2016-07-22. The company operates under Atrys brand name. Atrys is a clinical and translational research laboratory dedicated to the diagnosis, prognosis and treatment of cancer, including hematologic and solid malignancies. The company has four areas of activity: Laboratory, Telemedicine, Radiotherapy, as well as Research and Development (R&D). The firm has its diagnostic laboratories and translational research in Barcelona and Granada, and offices in Madrid, Spain.

View Section: Eyestock Rating